Merck & Co Inc (MRK) Common Stock USD0.50
$0.45
(0.62%)
- Add to watchlist
- This stock can be held in a
$0.45
(0.62%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.45
(0.62%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Merck to buy Pandion Therapeutics for $1.85bn
25 February 2021 15:01
(Sharecast News) - Merck has agreed to buy clinical-stage biotechnology company Pandion Therapeutics for $1.85bn.
-
AstraZeneca's breast cancer drug moves to early primary analysis
17 February 2021 07:52
(Sharecast News) - AstraZeneca said the phase 3 trial for breast cancer drug Lynparza would move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring...
-
AstraZeneca's Lynparza cancer drug approved by Japan
29 December 2020 07:02
(Sharecast News) - AstraZeneca and Merck's Lynparza has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers, the UK-based pharmaceutical company said on Tuesday.
-
Merck to buy Oncolmmune for $425m
23 November 2020 12:20
(Sharecast News) - Merck has agreed to buy privately-held, clinical-stage biopharmaceutical company OncoImmune for an upfront payment of $425m in cash.
-
Merck to pursue Covid-19 vaccine using same approach as against Ebola
26 May 2020 12:33
(Sharecast News) - US pharmaceutical giant Merck has penned an agreement with researchers at IAVI to develop a vaccine candidate against the novel coronavirus which provokes Covid-19 using the same...
-
Trump set to declare national emergency in US, freeing up funding
13 March 2020 16:53
(Sharecast News) - The US is expected to declare a national emergency at the end of the week and call for a coordinated international response to contain the coronavirus and its economic fallout.
-
Merck to buy Tilos Therapeutics for up to $773m
10 June 2019 11:54
(Sharecast News) - Drug maker Merck has agreed to buy privately-held biopharmaceutical group Tilos Therapeutics for up to $773m.
-
Peloton scraps IPO in favour of $1bn tie up with Merck
21 May 2019 13:41
(Sharecast News) - American drugs giant Merck has agreed to buy Peloton Therapeutics in a deal that could eventually be worth more than $2bn.
-
Merck to buy Antelliq Group for EUR2.1bn
14 December 2018 14:25
(Sharecast News) - Merck has agreed to buy privately-held French digital animal identification, traceability and monitoring solutions company Antelliq Group from funds advised by BC Partners for €2.1bn in...
-
Merck swings to a profit as Keytruda revenues soar
25 October 2018 14:50
(Sharecast News) - US drugmaker Merck swung to a $2bn profit in its last trading quarter, bouncing back from the small loss recorded a year earlier as a result of large one-time charges.
-
AstraZeneca and Merck get designation for Lynparza in pancreatic cancer
16 October 2018 08:03
(Sharecast News) - AstraZeneca, alongside Merck & Co, announced on Tuesday that the two parties have been granted orphan drug designation (ODD) by the US Food and Drug Administration for Lynparza...
-
AstraZeneca, Merck NF1 treatment granted orphan status by EMA
3 August 2018 07:52
(Sharecast News) - AstraZeneca and Merck said the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1) an...
Company announcements Announcements
No company announcements about Merck & Co Inc Common Stock USD0.50 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.